A Study to Evaluate the Safety and Effectiveness Transdermal Compress Device in Participants With Transfemoral Amputations

Prosthesis and Implants Clinical Trial

Official title:

A Prospective, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Effectiveness of the Transdermal Compress Device in Participants With Transfemoral Amputations

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06134167
• Other study ID #: BAL-448-001
• Status: Recruiting
• Phase: Phase 3
• Start date: June 2024
• Est. completion date: June 2031

Study information

• Verified date: June 2024
• Source: Balmoral Medical company
• Contact: Kristen Gault
• Phone: (508) 351-8632
• Email: kristen.gault[@]avaniaclinical.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of the Transdermal Compress device in participants with Transfemoral Amputations.

Description:

This study is a prospective, multicenter, single-arm, open-label study in skeletally mature participants with transfemoral limb loss (unilateral or bilateral), without bone or vascular disease who have or are anticipated to have rehabilitation problems with or cannot use a conventional socket prosthesis. Study participants will undergo surgical implantation of the Transdermal Compress device on Study Day 1. Participant progression including clinical assessments and prosthetic use will follow the study rehabilitation protocol. Events of special interest include superficial and deep infections at the implant site, failures, and secondary surgical interventions; participants will be followed for all soft tissue interface issues. Participants will be assessed for effectiveness and safety endpoints at baseline and at Months 6, 12, 18, and 24 and annually through 5 years post-implantation. Adverse events and adverse device effects will be collected and reported starting at the time of surgical implantation. Study participants will also be included in the Osseointegration Quality Registry in parallel to this study to allow for long-term follow-up post-study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: June 2031
• Est. primary completion date: December 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria

1. Participant must be able to understand the investigational nature of this study and has reviewed and provided written, informed consent prior to any study-specific procedures.

2. Participant is a skeletally mature male or female and is 18 - 65 years of age at screening. Participants < 22 years of age require radiographic confirmation of skeletal maturity and must have failed the use of conventional prosthesis.

3. Participant has an estimated BMI of = 18.5 and = 40 kg/m2 and weight = 245 lbs without prosthesis.

4. Participant has unilateral or bilateral transfemoral limb loss without bone or vascular disease.

5. Participant has problems with conventional prostheses or is not able to use a prosthesis at all or is anticipated to experience problems with a socket prosthesis in the investigator's judgment.

6. Participant has adequate bone stock to support the implanted device

7. Participant does not have any cortical defect located between the expected location of the anchor plug and spindle/bone interface.

8. Participant has the willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full length of the study including the prescribed rehabilitation program. Exclusion Criteria

1. Female participants who are pregnant, nursing, or have a planned pregnancy during the first 12 months post-surgical implantation.

2. Participant had a prior osseointegrated device implanted in the lower limb planned for the study device.

3. Participant has a history of systemic or localized infection at the residual limb site within 6 months prior to Study Day 1.

4. Participant has any distant foci of infections.

5. Participant has a history of sepsis within 6 months prior to Study Day 1.

6. Participant's length of the residual femur cannot accommodate the intramedullary portion of the Transdermal Compress device.

7. Participant has a femoral deformity that in the opinion of the treating surgeon results in an inability to properly insert the Transdermal Compress implant system, and/or results in alignment that is biomechanically unsound.

8. Participant does not have an adequate myofascial flap to allow for circumferential contact with the implanted device.

9. Participant has evidence of or history of severe peripheral vascular disease or insufficiency, muscular atrophy, neuromuscular disease, or diabetes mellitus (Type I or Type II).

10. Participant has evidence of or a documented history of osteomyelitis (excluding the history of osteomyelitis distal to amputation), systemic osteoporosis, or osteomalacia.

11. Participants with identified risk factors for osteoporosis must have a reported T-score > -2.5 within 6 months prior to Study Day 1.

12. Participant has evidence of or a documented history of severe metabolic disorders that may impair bone formation.

13. Participant has a history of systemically administered corticosteroids or immunosuppressive or immunomodulatory therapy or chemotherapy drugs.

14. Participant has known drug or alcohol dependence currently or within the last year.

15. Participant is a smoker, nicotine, or tobacco user in any form or who has used nicotine or tobacco-containing products within the past 6 months prior to Study Day 1.

16. Participant has any other condition, which in the opinion of the Investigator, precludes the participant's participation in the study or the participant is unlikely to comply with the protocol-defined

Related Conditions & MeSH terms

• Prosthesis and Implants

Intervention

Device:
• Transdermal Compress Device
Study participants will undergo surgical implantation of the Transdermal Compress device on Study Day 1. Participants will be followed through the end of the study as they complete rehabilitation.

Locations

Country	Name	City	State
United States	University of Colorado Anschutz Medical Campus	Aurora	Colorado
United States	The Johns Hopkins Hospital	Baltimore	Maryland
United States	Northwestern Memorial Hospital	Chicago	Illinois
United States	The Ohio State University Wexner Medical Center	Columbus	Ohio
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania
United States	UC Davis Medical Center	Sacramento	California
United States	Walter Reed Military Medical Center	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Balmoral Medical company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Radiographic Outcomes	Review images to determine: Spindle-Anchor Plug Gap measures > 0.0mm No Spindle-Anchor Plug gap loss No progressive radiolucencies No progressive cortical thinning No femoral shaft fracture No osteolysis at the bone-spindle interface No migration/subsidence No aseptic loosening. Implant integrity is intact.	Two (2) and Five (5) years post-implantation
Primary	The study primary endpoint is a composite endpoint to determine the proportion of participants who are successful on the primary effectiveness and safety endpoints (overall success) at 2 years	The following endpoint components will be used to assess effectiveness in the composite endpoint: Prosthetic Wear Time PROMIS Physical Function OPUS Satisfaction with Devices and Services; The following will be used to assess safety in the composite endpoint: Lack of secondary surgical intervention. No more than 2 superficial infections per year and no more than 3 superficial infections in the first two years post-implantation.; Radiographic success.	Two (2) years post-implantation
Secondary	Overall infection rate	Overall infection rate subclassified as deep or superficial to the fascia.	Two (2) and Five (5) years post-implantation
Secondary	Lack of secondary surgical intervention	Lack of secondary surgical intervention	Two (2) and Five (5) years post-implantation
Secondary	Orthotics and Prosthetics Users Survey: Satisfaction with Devices	21-item scale that measures satisfaction with the prosthetic device and care quality. Items are rated on 5 points (1 = Strongly agree to 5 = Strongly Disagree).	Two and Five (2-5) years post-implantation
Secondary	Prosthetic Wear Time	Prosthetic Wear Time- Hours per Day.	Two (2) and Five (5) years post-implantation
Secondary	Patient Reported Outcome Measurement Information System: Physical Function	Clinical outcome assessment (COA) that measures the patient's experience with the use of a transdermal device in that the primary goal is to improve physical function.: Physical Function. Items on are rated on 5 points (1 = unable to do. 5 = Without any difficulty).	Two (2) and Five (5) years post-implantation
Secondary	A composite endpoint will be evaluated to determine the proportion of participants who are successes on both the primary effectiveness and safety endpoints at 2 years and 5 years.	The following endpoint components will be used to assess effectiveness in the composite endpoint: Prosthetic Wear Time Patient Reported Outcome Measurement Information System: Physical Function Orthotics and Prosthetics Users Survey: Satisfaction with Devices	Two (2) and Five (5) years post-implantation
Secondary	The proportion of participants with no more than 2 superficial infections per year and no more than 3 superficial infections in the first two years post-implantation.	The proportion of participants with no more than 2 superficial infections per year and no more than 3 superficial infections in the first two years post-implantation.	Two (2) years post-implantation
Secondary	The proportion of participants who have had serious device-related adverse events.	The proportion of participants who have had serious device-related adverse events.	Two (2) and Five (5) years post-implantation
Secondary	Type and frequency of mechanical complications over time.	Any mechanical complications will be recorded and evaluated for device deficiencies.	Two (2) and Five (5) years post-implantation
Secondary	Patient Reported Outcome Measurement Information System: Pain Intensity	Pain Intensity domain measures self-reported pain on a scale of 0 (No Pain) to 10 (Worst imaginable pain).	Two (2) and Five (5) years post-implantation
Secondary	Patient Reported Outcome Measurement Information System: Pain Behavior	Measures self-reported external manifestations of pain: behaviors that typically indicate to others that an individual is experiencing pain.	Two (2) and Five (5) years post-implantation
Secondary	Patient Reported Outcome Measurement Information System: Pain Interference	They include observable displays (sighing, crying), pain severity behaviors (resting, guarding, facial expressions, and asking for help), and verbal reports of pain. The scale contains 7-question rating to evaluate pain behavior on a 6 point scale (1 = Had no pain, 6 = Always have pain	Two (2) and Five (5) years post-implantation